Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients

Liver Transplantation

Volumn 15, Issue 2, 2009, Pages 216-222

  Cabrera, Roniel ^a   Ararat, Miguel ^a   Soldevilla Pico, Consuelo ^a   Dixon, Lisa ^a   Pan, Jen Jung ^a   Firpi, Roberto ^a   Machicao, Victor ^a   Levy, Cynthia ^a   Nelson, David ^a   Morelli, Giuseppe ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LIVER ENZYME;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOASSAY; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 67649172198     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21666     Document Type: Article

References (41)

1. Charlton M. Hepatitis C infection in liver transplantation, Am J Transplant 2001;1:197-203.
2. Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992;89:1361-1365.
3. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
4. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
5. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28-S34.
6. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;28:756-763.
7. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8:S19-S27.
8. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003;9:S63-S66.
9. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
10. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32: 1125-1130.
11. Wiesner RH. Advances in diagnosis, prevention, and management of hepatic allograft rejection. Clin Chem 1994;40: 2174-2185.
12. Gomez-Manero N, Herrero JI, Quiroga J, Sangro B, Pardo F, Cienfuegos JA, Prieto J. Prognostic model for early acute rejection after liver transplantation. Liver Transpl 2001;7:246-254.
13. McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004;10:975-985.
14. Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl 2006;12:S38-S47.
15. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-645.
16. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998;29:143-150.
17. Tippner C, Nashan B, Hoshino K, Schmidt-Sandte E, Akimaru K, Boker KH, Schlitt HJ. Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course. Transplantation 2001;72:1122-1128.
18. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C. Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999;5:S107-S114.
19. Regev A, Molina E, Moura R, Bejarano PA, Khaled A, Ruiz P, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004;10: 1233-1239.
20. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003;17:77-88.
21. Zeevi A, Britz JA, Bentlejewski CA, Guaspari D, Tong W, Bond G, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005;15:17-24.
22. Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, et al. A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Transplant Proc 2005;37:3538-3541.
23. Zeevi A, Husain S, Spichty KJ, Raza K, Woodcock JB, Zaldonis D, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007;7:471-475.
24. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663-668.
25. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006;20:689-694.
26. Thai NL, Blisard D, Tom K, Basu A, Smetanka C, Tan H, et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation 2006;82:1649-1652.
27. Batal I, Zeevi A, Heider A, Girnita A, Basu A, Tan H, et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol 2008;129:587-591.
28. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-1247.
29. Sottong PR, Rosebrock JA, Britz JA, Kramer TR. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 2000;7:307-311.
30. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
31. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
32. Demetris AJ, Eghtesad B, Marcos A, Ruppert K, Nalesnik MA, Randhawa P, et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004;28:658-669.
33. US Department of Health and Human Services. Class II special controls guidance documents: cyclosporin and tacrolimus assays; draft guidance for industry and FDA. Available at: http://www.fda.gov/cdrh/ode/guidance/ 1380.pdf. Accessed September 2008.
34. McCaughan GW, Davies JS, Waugh JA, Bishop GA, Hall BM, Gallagher ND, et al. A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: the use of monoclonal antibodies and double immunolabeling. Hepatology 1990;12:1305-1313.
35. Martinez OM, Rosen HR. Basic concepts in transplant immunology. Liver Transpl 2005;11:370-381.
36. Perrella O, Sbreglia C, Arenga G, Perrella A, Ferrara A, D'Antonio A, et al. Acute rejection after liver transplantation: is there a specific immunological pattern? Transplant Proc 2006;38:3594-3596.
37. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation. Hepatology 2005;41:72-81.
38. Smith MW, Walters KA, Korth MJ, Fitzgibbon M, Proll S, Thompson JC, et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006;130:179-187.
39. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, Nelson DR. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004;40:1062-1071.
40. Folgori A, Spada E, Pezzanera M, Ruggeri L, Mele A, Garbuglia AR, et al. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut 2006;55:1012-1019.
41. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999;117:926-932.